Cycle on Jun 28, 2026

I will start by listing the open threads and watches for this topic. This will help identify any specific queries or tracked events that require resolution or updates during this cycle.

I will perform web searches to check the status of the Amgen Tavneos public docket/FDA hearing submission (which has a fire date around now, June 29, 2026), and to search for other recent, high-impact science and health news from the past week (June 21–28, 2026).

I will try a broader search for "Amgen Tavneos" or "Tavneos FDA" or "Tavneos withdrawal" to see if there are any recent updates from the past week. I'll also look for other major health/science news.

This is a major regulatory development! The European Medicines Agency's CHMP has recommended revoking the marketing authorization for Amgen's Tavneos (avacopan), citing serious data integrity and safety concerns, just as the FDA hearing and public docket close is looming in the US on June 29, 2026. Let's fetch a couple of these articles to get precise details and quotes: - `https://www.fiercepharma.com/pharma/chmp-reverses-marketing-recommendation-amgens-tavneos-fda-hearing-looms` (Fierce Pharma, June 26, 2026) - `https://www.reuters.com/business/healthcare-pharmaceuticals/ema-recommends-revoking-marketing-authorisation-amgens-rare-disease-drug-2026-06-26/` (Reuters, June 26, 2026) - Let's check `https://www.biocentury.com/article/659929/chmp-joins-fda-in-challenging-tavneos-approval-basis` (if we can read it, or another source like WSJ if we can fetch it, or Medcity News). Let's fetch the Fierce Pharma and Reuters articles.

This is incredibly rich and detailed. Let's look at the key details: 1. **Amgen Tavneos:** - The EMA's CHMP recommended **revoking** the EU marketing authorization for Amgen/CSL Vifor's Tavneos (avacopan). - Why? The CHMP determined that the pivotal 331-patient ADVOCATE study was "conducted in breach of good clinical practice (GCP) principles" and the data compiled "were found to be incorrect and misleading and could no longer be relied upon for demonstrating Tavneos' effectiveness." - In the U.S., Amgen was granted a one-month extension by the FDA on its data deadline for the hearing, which is now **July 29, 2026** (instead of late June). - This directly updates the watch `Amgen Tavneos FDA hearing submission and public docket close` (id `019ec855-5381-7936-a3b6-a40d207e679d`), as the deadline has been extended to July 29, 2026! We should record an event or update/re-target this watch since it hasn't closed yet. We can record an event showing the extension and keep it open (or update the watch). Let's check how we want to handle the watch. 2. **Omeros's Yartemlea (narsoplimab):** - The article notes: "the CHMP also handed out negative opinions to ... Yartemlea, from Omeros, to treat adults and kids ages two and older with hematopoietic stem cell transplant (HSCT)-associated thrombotic microangiopathy [HSCT-TMA]." - This matches our watch `EMA re-examination outcome on Omeros's narsoplimab in TA-TMA` (id `019f0620-0add-7ac7-9db1-1ce428418522`). The CHMP has issued a negative opinion for Yartemlea (narsoplimab) in HSCT-TMA at its June 2026 meeting. Let's search specifically for Omeros Yartemlea to see if they've requested re-examination or if this is the final final decision. Let's do a search. Let's do a web search for Omeros Yartemlea CHMP to see the exact details of the negative opinion and whether they are requesting re-examination. This will help us resolve or update that watch.

Let's fetch the Omeros press release or an article to get the exact details of the negative CHMP opinion, and their plan for re-examination. I'll fetch `https://investor.omeros.com/news/news-details/2026/Omeros-Corporation-Announces-Update-on-European-Marketing-Authorization-Application-for-Narsoplimab-in-TA-TMA/default.aspx` or `https://www.stocktitan.net/news/OMER/omeros-corporation-announces-update-on-european-marketing-v1qilrb9rhrf.html`. Let's fetch the stocktitan one or the tipranks one. Let's fetch stocktitan.

This is perfect. The watch `EMA re-examination outcome on Omeros's narsoplimab in TA-TMA` (id `019f0620-0add-7ac7-9db1-1ce428418522`) is for: "Monitor Omeros's request for re-examination of the negative CHMP opinion for narsoplimab in TA-TMA, the convening of the Ad Hoc Expert Group (AHEG), and the final decision." The trigger is: "Fires when the EMA or Omeros announces the outcome of the re-examination and AHEG review." So this watch is still ongoing because they've just announced they *intend* to request re-examination and seek review by the AHEG. We should record a progress event on it (or we can just keep track of it, but since it's a `one_shot` watch tracking the *outcome* of the re-examination, it doesn't resolve yet. We will record an event showing the negative CHMP opinion was adopted on June 26, 2026, and Omeros announced its intent to request re-examination and seek AHEG review). Let's do a search for other major health/science developments from the past week (June 21–28, 2026) to see if there are other findings we should write. For example: - Are there any updates on other vaccines, clinical trials, or space/energy/biology breakthroughs? - Let's search for "FDA approval" in the past week. - Let's search for "clinical trial results" or "Phase 3 results" in the past week. - Let's search for "outbreak" or "public health" in the past week. - Let's search for "space" or "NASA" or "ISS" in the past week (especially since we have an ISS Russian Zvezda module leak watch, let's check that!). Let's search for "ISS Zvezda leak" or "International Space Station leak". - Let's search for "HHS clinical trials reform Operation Trailblazer" since there was a prior finding on it. Let's see if there are any updates on it. - Let's search for "MaaT013 CHMP negative opinion" (from the Fierce Pharma article, it noted MaaT Pharma got a negative CHMP opinion on MaaT013 / Xervyteg on June 26, 2026). - Let's search for "Acadia Daybu CHMP positive opinion" (from the Fierce Pharma article, Acadia got a positive CHMP opinion on Daybu / trofinetide on reexamination). Let's run these searches. First, the ISS leak search.

Wait, this is an incredible, highly salience story! Let's fetch one of these articles. "ISS leak standoff forces NASA crew into Dragon shelter" or "Astronauts on International Space Station shelter in SpaceX Dragon as cosmonauts try to fix air leak". Let's fetch "ISS leak standoff forces NASA crew into Dragon shelter" (or similar) from MSN or another source to see what exactly happened. Wait, let's search for "ISS leak standoff forces NASA crew into Dragon shelter" on MSN, or let's do a search to find the original source or an accessible URL. Let's fetch the MSN link: `https://www.msn.com/en-us/news/insight/iss-leak-standoff-forces-nasa-crew-into-dragon-shelter/gm-GMBFA99035` or another web fetch if possible. Wait, let's check `https://www.msn.com/en-us/news/insight/iss-leak-standoff-forces-nasa-crew-into-dragon-shelter/gm-GMBFA99035` - wait, sometimes MSN URLs can be long or redirects. Let's see if we can find a direct space news site like Spaceflight Now, Space.com, or similar. Let's search for `ISS leak Dragon shelter June 2026` or similar. Let's do a web search.

This is a massive story: "Cracks in the International Space Station are causing air leaks – how much longer can it remain habitable?" (The Conversation, June 25, 2026). And "NASA, Roscosmos clash over ISS crack repairs amid safety fears" / "ISS leak standoff forces NASA crew into Dragon shelter". Let's fetch `https://theconversation.com/cracks-in-the-international-space-station-are-causing-air-leaks-how-much-longer-can-it-remain-habitable-286060` to get the details of this standoff and leak issue. This matches our ongoing watch `ISS Russian Zvezda module air leaks and repairs` (id `019ea447-7d90-733c-acee-2eb6c1313c78`). Let's fetch this first.

This is a fantastic update for the ISS Russian Zvezda module air leaks watch (id `019ea447-7d90-733c-acee-2eb6c1313c78`). Let's review the details: - On **June 5, 2026**, NASA ordered five astronauts (sheltering inside SpaceX Crew Dragon) to prepare to abandon ship due to a worsening air leak in the Russian Zvezda module's PrK transfer tunnel. - The leak rate rose and new cracks appeared in early June 2026. - Roscosmos proposed repairs using a drill, which NASA rejected. Roscosmos then proposed using a saw to remove a load-bearing bracket in the tunnel. NASA balked at this as well, leading to the emergency shelter order. - Both repair plans were abandoned, and the shelter order was lifted after 1.5 hours. - Roscosmos has now agreed to permanently close off the PrK tunnel from the rest of the station to isolate the leak. - The US Senate Commerce Committee recently passed the NASA Authorization Act, which would delay ISS decommissioning from 2030 until **2032**, to prevent a gap in US low-Earth orbit presence before commercial replacements (like Vast's Haven-1/Haven-2, Axiom, or Starlab) are fully ready. Let's record a progress event on `ISS Russian Zvezda module air leaks and repairs` (id `019ea447-7d90-733c-acee-2eb6c1313c78`), as this is an ongoing watch but has had a major, high-salience event. Let's do some more searches to see what else has happened in the past week: - Are there any updates on other watches? Let's check: - `Amgen Tavneos FDA hearing submission and public docket close` (id `019ec855-5381-7936-a3b6-a40d207e679d`): This watch was set to fire on June 29, 2026. However, Amgen was granted an extension to **July 29, 2026** for its data deadline. We should record a progress event for this and update the watch's fire date/details. Let's verify if we can update a watch, or if we should just record an event and keep it open. - Let's check `Belite Bio completed rolling NDA submission for tinlarebant in rare retinal disease` / `FDA filing acceptance and PDUFA date for Belite Bio's tinlarebant` (id `019ec855-8c35-71a4-b33b-90db344bf45d`). Let's search if there has been any update on Belite Bio's tinlarebant in the past week. - Let's check `HHS and FDA Formally Launch "Operation Trailblazer"` (slug `hhs-clinical-trials-reform-operation-trailblazer`). The launch was on June 22, 2026. Let's search for "Operation Trailblazer" and "Robert F. Kennedy" or "HHS" or "FDA" to see if there are any new details or follow-ups. - Let's check `Capricor's deramiocel in DMD cardiomyopathy` (id `019f061f-f34a-7079-a276-d216329928b2`): "Monitor the FDA Cellular, Tissue, and Gene Therapies Advisory Committee meeting scheduled for July 29, 2026". Let's search if there's any update on this. - Let's check if there are any other disease outbreaks or public health moves, e.g., bird flu / H5N1, mpox, dengue, or Covid. Let's do a general search for "outbreak" or "public health" or "H5N1" or "FDA approval" in the past week. Let's run a web search for "Operation Trailblazer" and "clinical trials" to see if there are updates.

Let's fetch `https://thehill.com/policy/healthcare/5934886-us-china-clinical-trial-competition/` and `https://www.raps.org/resource/hhs-and-fda-propose-clinical-trial-reforms-to-expedite-drug-development.html` to get more detailed information about the specific actions of Operation Trailblazer, such as the pilot program for qualified external institutions and the QSP approach. This will allow us to update the prior finding on Operation Trailblazer (`hhs-clinical-trials-reform-operation-trailblazer`) with the concrete details that came out during the launch week! Let's do that.

This is an incredibly rich, direct update! Let's review what we have: - Under **Operation Trailblazer** (formally launched June 22, 2026, by HHS Secretary Robert F. Kennedy Jr. under the Trump administration), the FDA has announced several concrete reform measures: 1. An **Expedited IND (Investigational New Drug) pilot program** aimed at reducing the time from drug identification to first-in-human (FIH) Phase 1 trials by partnering sponsors with "qualified research institutions" (academic medical centers/CROs) for rolling IND submissions to avoid clinical holds. Public docket opened for comments until July 22, 2026. 2. A major revised **draft guidance** entitled "Demonstrating Substantial Evidence of Effectiveness for Human Drug and Biological Products", which codifies the shift championed by former Commissioner Marty Makary to allow developers to rely on **only one** rigorous pivotal clinical trial plus confirmatory evidence for approval (instead of the traditional two). Comments are due August 24, 2026. 3. A draft guidance on **Quantitative Systems Pharmacology (QSP)-based dose selection** to determine the Minimum Anticipated Biological Effect Level (MABEL) dose in Phase 1 trials, moving away from historical animal toxicology models. Comments due July 24, 2026. 4. Updated draft guidance on **master protocols** (basket, umbrella, and platform trials). 5. The launch of the **"Phase 1 IND Navigator" webpage** and a new CMC (Chemistry, Manufacturing, and Control) webpage clarifying phase-specific requirements to prevent sponsors from over-submitting data prematurely. 6. A new **Phase 1 Call Center** to provide real-time regulatory answers. This is a beautiful, direct, substantial update to our existing finding `hhs-clinical-trials-reform-operation-trailblazer`. We will update that note with these concrete details and quotes! Let's check if there are any other major health and science news from the last week. Let's search for "FDA approval" or "clinical trial" or "Phase 3" in the past week to see if there are other major breakthroughs.

Whoa, there are some very interesting phase 3 clinical trial results here! Let's examine: 1. **Pfizer Sigvotatug Vedotin Phase 3 Results (June 22, 2026):** - Pfizer announced topline Phase 3 results for sigvotatug vedotin in previously treated metastatic non-squamous non-small cell lung cancer (NSCLC). - Let's search for this to see what the results were. Did it meet its primary endpoint? 2. **BridgeBio Infigratinib Phase 3 PROPEL 3 Trial in Achondroplasia (June 29, 2026):** - "BridgeBio Announces Publication in the New England Journal of Medicine of Phase 3 PROPEL 3 Trial of Oral Infigratinib in Children Living with Achondroplasia" - It met height-velocity and height Z-score endpoints, and BridgeBio plans an FDA filing in Q3 2026 and U.S. launch in early to mid 2027. This is a major breakthrough in pediatric rare disease! Let's look into this. 3. **AstraZeneca Efzimfotase Alfa Phase 3 MULBERRY Trial in Hypophosphatasia (June 29, 2026):** - "Efzimfotase alfa demonstrated improvements in bone health in treatment-naïve pediatric patients with hypophosphatasia... in MULBERRY Phase III trial" 4. **Exelixis Phase 3 STELLAR-303 Trial of Zanzalintinib (June 2026, let's check date):** - "Exelixis Provides Update on the Phase 3 STELLAR-303 Trial Evaluating Zanzalintinib..." Let's check if this is zanzalintinib plus Tecentriq in late-line metastatic colorectal cancer (mCRC). We have a watch on: - `FDA regulatory decision on Exelixis' zanzalintinib plus Tecentriq in late-line mCRC` (id `019ef183-e5e2-7bb3-a1c8-77e7ca537bb4`) with a PDUFA target action date of December 3, 2026. - Let's see what the update on the STELLAR-303 trial was. Did it fail or succeed? This is highly relevant to that watch! 5. **Universal COVID Vaccine (DIOSynVax AI-designed vaccine) Clears Phase 1 Human Trial (June 2026):** - "Universal COVID Vaccine Clears First Human Trial as Researchers Caution It Is Still Years Away" - Wait, we have a watch: `DIOSynVax AI-designed universal Sarbeco vaccine Phase II trial readout` (id `019eae92-8dcc-7b60-a056-0e3068a0f4e8`). This article mentions a Phase 1 trial. Let's see if this is related. Let's do some targeted searches on these! First: Pfizer's sigvotatug vedotin Phase 3 results. Let's search for it.

This is a massive pharmaceutical story! Pfizer's sigvotatug vedotin (an investigational first-in-class integrin beta-6 targeting ADC acquired in the $43 billion Seagen acquisition) failed to meet the primary endpoint of overall survival (OS) compared to docetaxel in the Phase 3 SigVie-002 study (previously known as SGNB6A-002 or similar) for previously treated metastatic non-squamous non-small cell lung cancer (NSCLC). This is the third Seagen-acquired ADC to disappoint or fail a late-stage trial in roughly a year, calling Pfizer's high-stakes oncology/ADC strategy into question. Let's fetch `https://www.biopharmadive.com/news/pfizer-sigvotatug-vedotin-lung-cancer-results-seagen/823501/` or `https://www.fiercebiotech.com/biotech/pfizer-first-new-adc-seagen-acquisition-fails-phase-3-nsclc-trial` to read the exact details and get verbatim quotes. Let's fetch the BioPharma Dive one.

This is an exceptional finding! Let's write a note on this (`pfizer-sigvotatug-vedotin-phase-3-lung-cancer-fail`). Let's see: "Pfizer late-stage ADC lung cancer fail calls cancer strategy into question." We can write a beautiful note detailing: - The failure of the Phase 3 SigVie-002 study of sigvotatug vedotin (an integrin beta-6 targeting ADC acquired in the $43B Seagen deal) in previously treated metastatic non-squamous non-small cell lung cancer (NSCLC). - It missed the primary endpoint of overall survival (OS) compared to docetaxel. - This is a big blow to Pfizer's post-Seagen oncology growth narrative, which has already seen $4.5B in write-offs. - However, Pfizer remains optimistic about an ongoing study evaluating the drug in combination with Keytruda in first-line lung cancer, with data expected in 2027. Let's look into the other developments: 1. **BridgeBio's achondroplasia drug infigratinib NEJM Phase 3 data (June 29, 2026):** - Let's search for this to see the exact details of the PROPEL 3 trial. Is this a major step? Yes! Achondroplasia is a rare genetic condition (dwarfism) with few treatments (Voxzogo by BioMarin is currently approved). Infigratinib is an oral FGFR3 inhibitor. - Let's do a search.

Let's fetch `https://www.stocktitan.net/news/BBIO/bridge-bio-announces-publication-in-the-new-england-journal-of-o2jcwabskf27.html` to get the details of the PROPEL 3 trial of infigratinib in achondroplasia. This is a very important development! It represents a highly competitive oral alternative to BioMarin's daily-injection Voxzogo (vosoritide). Let's fetch it.

This is a massive and high-impact therapeutic breakthrough! We should write a dedicated finding on BridgeBio's infigratinib: `bridgebio-infigratinib-achondroplasia-nejm-phase-3`. Let's see: - BridgeBio published its Phase 3 PROPEL 3 trial results for **oral infigratinib** in children with achondroplasia in the *New England Journal of Medicine* (NEJM) on June 29, 2026. - It met the primary endpoint with a highly significant annualized height velocity (AHV) difference vs placebo of **+1.74 cm/year** (LS mean) or **+2.10 cm/year** (observed mean). - It also met key secondary endpoints, including height Z-score (+0.41 SD at Week 52), body proportionality (LS mean difference -0.05 in children <8 years), and arm span Z-score (+0.37 SD). - Safe and well-tolerated: no study-drug-related serious adverse events or discontinuations. - It represents a major competitive threat to BioMarin's daily-injection Voxzogo (vosoritide), as infigratinib is a once-daily **oral** pill. - BridgeBio plans to submit an NDA to the FDA in **Q3 2026** and an MAA to the EMA in **H2 2026**, targeting a U.S. launch in early-to-mid 2027. Let's check the other developments: 1. **Universal COVID Vaccine (DIOSynVax AI-designed vaccine) Clears Phase 1 Human Trial (June 2026):** - Let's search for "DIOSynVax" or "universal covid vaccine ai designed" to see the details of this Phase 1 trial. - We have a watch: `DIOSynVax AI-designed universal Sarbeco vaccine Phase II trial readout` (id `019eae92-8dcc-7b60-a056-0e3068a0f4e8`). The watch description mentions: "Monitor the Phase II clinical trial readout for DIOSynVax's universal Sarbeco vaccine designed entirely by AI (enrolling over 200 participants)." Let's search the latest news on DIOSynVax to see if the Phase 2 trial has read out, or if this is the Phase 1 trial publication. Let's do a search.

Let's fetch `https://www.techtimes.com/articles/319059/20260625/ai-designed-universal-coronavirus-vaccine-passes-first-human-trial-cambridge-team-eyes-phase-ii.htm` or `https://www.medicaldaily.com/universal-covid-vaccine-ai-designed-phase-1-trial-2026-timeline-475814` to get details about this universal COVID vaccine designed by AI. This is a very cool story! It represents the first human clinical trial results of a universal coronavirus vaccine designed entirely by AI (the pEVAC-PS vaccine by DIOSynVax/University of Cambridge). Let's fetch the TechTimes or Medical Daily article. Let's fetch TechTimes.

This is a spectacular set of findings! The web search budget is spent, which is the perfect cue to synthesize and write up these findings. Let's carefully assess our findings and the threads/watches: 1. **Omeros's Yartemlea (narsoplimab) Negative CHMP Opinion:** - Watch: `EMA re-examination outcome on Omeros's narsoplimab in TA-TMA` (id `019f0620-0add-7ac7-9db1-1ce428418522`). - Outcome: On June 26, 2026, the EMA's CHMP adopted a negative opinion on Omeros's MAA for narsoplimab (Yartemlea) in TA-TMA. Omeros announced its intent to request re-examination and seek review by an Ad Hoc Expert Group (AHEG). - Since the watch is for the *outcome* of the re-examination and AHEG review, it is still ongoing (`resolves: false`). We will record a progress event on it. - Let's write a note on this? Wait, we can write a note about the CHMP negative opinions this week (including Omeros and MaaT Pharma, and Acadia's reversal). Or we can update the existing prior finding `The Post-Makary FDA Pivot: Reversals, Resubmissions, and a Return to Advisory Committees` (slug `fda-regulatory-pivot-advisory-committees-capricor-replimune`) or write a new note. Wait, let's write a note focusing on the CHMP June 2026 meeting decisions (`chmp-june-2026-decisions-omeros-maat-pharma-acadia`) or keep things focused. Omeros's Yartemlea is a major story. Let's write a note for Omeros's EU rejection and plans for re-examination: `omeros-narsoplimab-yartemlea-eu-chmp-rejection`! 2. **Amgen Tavneos (avacopan) EU Revocation Recommendation & US Deadline Extension:** - Watch: `Amgen Tavneos FDA hearing submission and public docket close` (id `019ec855-5381-7936-a3b6-a40d207e679d`). - Outcome: On June 26, 2026, the EMA's CHMP recommended revoking the EU marketing authorization for Tavneos due to data integrity concerns from the pivotal ADVOCATE study (which they found was "conducted in breach of good clinical practice (GCP) principles" and of "incorrect and misleading" data). - In the U.S., the deadline for Amgen's FDA hearing submission has been extended from late June to **July 29, 2026**. - This is a major, high-salience development. We will record an event on the watch `Amgen Tavneos FDA hearing submission and public docket close` showing the deadline was extended to July 29, 2026 (resolves: false, since we keep watching until July 29). We should also write a detailed finding note on this: `amgen-tavneos-eu-revocation-us-fda-extension`. 3. **Operation Trailblazer formal launch week details:** - Prior finding: `HHS and FDA Formally Launch "Operation Trailblazer" to Sweepingly Reform U.S. Clinical Trials and Counter China` (slug `hhs-clinical-trials-reform-operation-trailblazer`). - We have new concrete details published during the launch week of June 22, 2026: - The Expedited IND pilot program (rolling IND submission platform with CROs/academic centers to minimize clinical holds; comments due July 22). - The revised draft guidance "Demonstrating Substantial Evidence of Effectiveness for Human Drug and Biological Products" allowing single pivotal trial + confirmatory evidence for approval (comments due August 24). - The draft guidance on Quantitative Systems Pharmacology (QSP)-based dose selection to determine MABEL dose in Phase 1 trials (comments due July 24). - Master protocols update (basket, umbrella, platform trials). - Launch of Phase 1 IND Navigator and CMC requirements webpages, plus a Phase 1 Call Center. - We will update the existing finding `hhs-clinical-trials-reform-operation-trailblazer` with these newly published details! 4. **ISS Russian Zvezda Module Air Leaks - June 2026 Emergency Shelter Standoff:** - Watch: `ISS Russian Zvezda module air leaks and repairs` (id `019ea447-7d90-733c-acee-2eb6c1313c78`). - Outcome: On June 5, 2026, NASA ordered five astronauts to shelter in SpaceX Crew Dragon due to a worsening leak rate and new cracks in the PrK transfer tunnel. This was triggered by a standoff where NASA rejected risky Roscosmos repair plans (first using a drill, then using a saw to remove a load-bearing bracket). The shelter order was lifted after 1.5 hours when Roscosmos dropped the plans. Roscosmos has now agreed to permanently close off the PrK tunnel from the rest of the station. - Legislative update: The U.S. Senate Commerce Committee passed the NASA Authorization Act, which would delay ISS decommissioning from 2030 until **2032** to ensure no gap before commercial replacements (like Vast's Haven-1/Haven-2, Axiom, or Starlab) are ready. - We will record a progress event on the ongoing watch `ISS Russian Zvezda module air leaks and repairs` (resolves: false, as it's an ongoing watch). We will write a dedicated note: `iss-zvezda-leak-standoff-decommissioning-extension`. 5. **Pfizer's Sigvotatug Vedotin Phase 3 Fail in Lung Cancer:** - Finding: Pfizer's Seagen-acquired ADC sigvotatug vedotin missed its primary overall survival (OS) endpoint vs docetaxel in the Phase 3 SigVie-002 study for previously treated metastatic non-squamous NSCLC. This is the third Seagen-acquired ADC setback in a year, challenging Pfizer's $43B oncology strategy. However, first-line combination trials with Keytruda are ongoing (data in 2027). - Let's write a note: `pfizer-sigvotatug-vedotin-phase-3-lung-cancer-fail`. 6. **BridgeBio's Oral Infigratinib Phase 3 NEJM Publication in Achondroplasia:** - Finding: On June 29, 2026, BridgeBio published Phase 3 PROPEL 3 results for oral infigratinib in children with achondroplasia in NEJM. It met primary and secondary endpoints (annualized height velocity difference of +1.74 cm/year vs placebo, height Z-score +0.41 SD, arm span Z-score +0.37 SD) with an excellent safety profile. It represents a major oral competitor to BioMarin's injectable Voxzogo. BridgeBio plans FDA NDA submission in Q3 2026. - Let's write a note: `bridgebio-infigratinib-achondroplasia-nejm-phase-3`. 7. **DIOSynVax AI-Designed Universal Coronavirus Vaccine Phase 1 Results:** - Watch: `DIOSynVax AI-designed universal Sarbeco vaccine Phase II trial readout` (id `019eae92-8dcc-7b60-a056-0e3068a0f4e8`). - Outcome: DIOSynVax and University of Cambridge published Phase 1 human trial results for the AI-designed pan-sarbecovirus vaccine candidate pEVAC-PS in the *Journal of Infection* in June 2026. The vaccine (a DNA plasmid delivered needle-free via the PharmaJet Tropis device) was safe and well-tolerated in 39 healthy adults, generating cross-reactive immune responses against SARS-CoV-1, SARS-CoV-2, and bat coronaviruses. However, researchers noted modest and variable immunogenicity due to high pre-existing background immunity in participants. A Phase 2 trial of 200 participants is currently underway to further assess efficacy. - This is a progress update for the watch. We will record a progress event on `DIOSynVax AI-designed universal Sarbeco vaccine Phase II trial readout` (resolves: false, as we are waiting for the Phase 2 readout). We will also write a note: `diosynvax-ai-universal-coronavirus-vaccine-phase-1`. Let's proceed systematically: 1. Write/update the notes. 2. Record the events on watches. 3. Finish the cycle. Let's write the first note: `amgen-tavneos-eu-revocation-us-fda-extension` (Amgen Tavneos EU Revocation Recommendation & US Deadline Extension).

Now let's write the second note: `omeros-narsoplimab-yartemlea-eu-chmp-rejection` (Omeros narsoplimab/Yartemlea EU CHMP rejection and plans for re-examination). Let's do that.

Now let's update the third note: `hhs-clinical-trials-reform-operation-trailblazer` (HHS and FDA Formally Launch "Operation Trailblazer" to Sweepingly Reform U.S. Clinical Trials and Counter China). Let's review the prior finding's title and contents (from the metadata: "On June 22, 2026, the U.S. Department of Health and Human Services (HHS), led by Secretary Robert F. Kennedy, Jr., in coordination with the FDA, NIH, and other federal agencies, formally launched…"). We will update it to carry the newly released concrete details of the launch week. Let's write the updated body.

Fantastic! Next, let's write the fourth note: `iss-zvezda-leak-standoff-decommissioning-extension` (ISS Russian Zvezda Module Air Leaks - June 2026 Emergency Shelter Standoff & 2032 Decommissioning Extension). Let's do that.

Now let's write the fifth note: `pfizer-sigvotatug-vedotin-phase-3-lung-cancer-fail` (Pfizer's Sigvotatug Vedotin Phase 3 Fail in Lung Cancer). Let's do that.

Now let's write the sixth note: `bridgebio-infigratinib-achondroplasia-nejm-phase-3` (BridgeBio's Oral Infigratinib Phase 3 NEJM Publication in Achondroplasia). Let's do that.

Now let's write the seventh note: `diosynvax-ai-universal-coronavirus-vaccine-phase-1` (DIOSynVax AI-designed universal coronavirus vaccine Phase 1 results). Let's do that.

This is an amazing and comprehensive set of updates! Let's record events for the watches that have moved. Let's review our active watches: 1. `Amgen Tavneos FDA hearing submission and public docket close` (id `019ec855-5381-7936-a3b6-a40d207e679d`): - The fire date was June 29, 2026. - Event: Amgen won a one-month extension. The deadline is now **July 29, 2026**. - Let's record a progress event on it. Since the deadline is extended, we keep the watch open (`resolves: false`). Let's use `record_event`. 2. `EMA re-examination outcome on Omeros's narsoplimab in TA-TMA` (id `019f0620-0add-7ac7-9db1-1ce428418522`): - Event: The CHMP adopted a negative opinion on June 26, 2026. Omeros intends to request re-examination and seek AHEG review. - Since the watch is for the *outcome* of the re-examination and AHEG review, it is still ongoing (`resolves: false`). We will record a progress event on it. 3. `DIOSynVax AI-designed universal Sarbeco vaccine Phase II trial readout` (id `019eae92-8dcc-7b60-a056-0e3068a0f4e8`): - Event: In June 2026, DIOSynVax/Cambridge published Phase 1 human safety and immunogenicity results for pEVAC-PS in the *Journal of Infection*. A Phase 2 trial of 200 participants is currently underway. - Since this is a Phase 1 publication and the watch is for the Phase 2 trial readout, the watch is still ongoing (`resolves: false`). We will record a progress event on it. 4. `ISS Russian Zvezda module air leaks and repairs` (id `019ea447-7d90-733c-acee-2eb6c1313c78`): - Event: On June 5, 2026, worsening leaks led to an emergency shelter standoff where NASA ordered astronauts into SpaceX Crew Dragon to prepare to abandon ship. Roscosmos dropped risky repair plans and agreed to permanently close off the PrK tunnel. - This is an ongoing watch (`resolves: false`). We will record a progress event on it. Let's call `record_event` on these four watches. First: Amgen Tavneos FDA hearing submission.

Second: Omeros's narsoplimab in TA-TMA.

Third: DIOSynVax AI-designed universal Sarbeco vaccine.

Fourth: ISS Russian Zvezda module air leaks and repairs.

We have recorded all the relevant events, written and updated all our notes, and fully addressed the brief with high-quality, primary-source-grounded evidence from this cycle. Let's call `finish_cycle` to complete this research cycle.

I have successfully completed the research cycle! Here is a summary of the findings and updates recorded during this cycle: ### 1. **Amgen's Tavneos (Avacopan) Regulatory Crisis Deepens** * **What Happened:** On June 26, 2026, the European Medicines Agency's (EMA) CHMP recommended **revoking the marketing authorization** for Amgen/CSL Vifor's rare-disease drug Tavneos. The committee found that the pivotal 331-patient ADVOCATE study was conducted in breach of Good Clinical Practice (GCP) principles, rendering its effectiveness data "incorrect and misleading." * **U.S. Update:** In the U.S., where the FDA has also proposed withdrawing the drug due to drug-induced liver injury risks, Amgen secured a one-month extension for its formal hearing submission. The new deadline is **July 29, 2026**. * **Durable Slug:** `amgen-tavneos-eu-revocation-us-fda-extension` *(New Finding)* * **Watch Event:** Recorded progress on the active watch `Amgen Tavneos FDA hearing submission and public docket close` (extended to July 29, 2026). ### 2. **Omeros's Yartemlea (Narsoplimab) Rejected in Europe** * **What Happened:** The EMA's CHMP adopted a negative opinion on Omeros's Marketing Authorization Application (MAA) for Yartemlea in transplant-associated thrombotic microangiopathy (TA-TMA). Yartemlea was approved in the U.S. in December 2025. * **Next Steps:** Omeros announced its intent to request an official re-examination of the decision and seek a review by an independent Ad Hoc Expert Group (AHEG). * **Durable Slug:** `omeros-narsoplimab-yartemlea-eu-chmp-rejection` *(New Finding)* * **Watch Event:** Recorded progress on the active watch `EMA re-examination outcome on Omeros's narsoplimab in TA-TMA`. ### 3. **Operation Trailblazer: Launch Week Details Unveiled** * **What Happened:** Following the formal launch on June 22, 2026, by HHS Secretary Robert F. Kennedy, Jr., the FDA released concrete reform measures to counter the clinical trial offshoring threat to China: 1. An **Expedited IND Pilot Program** utilizing rolling submissions with academic medical centers/CROs to reduce early-stage timelines by six to twelve months. 2. A paradigm-shifting revised **draft guidance** codifying a policy to allow **single pivotal clinical trials** (plus confirmatory evidence) for drug approvals instead of the traditional two. 3. Draft guidance on **Quantitative Systems Pharmacology (QSP)** to determine human Phase 1 starting doses, moving away from slow animal toxicology models. 4. Web resources, including the **Phase 1 IND Navigator** and a dedicated Phase 1 Contact Center. * **Durable Slug:** `hhs-clinical-trials-reform-operation-trailblazer` *(Updated Finding)* ### 4. **ISS Russian Zvezda Module Leak Standoff and 2032 Extension** * **What Happened:** On June 5, 2026, worsening leaks and a standoff over risky repair proposals (Roscosmos proposed using a drill and then a saw to remove a load-bearing bracket) led NASA to order five astronauts to **shelter inside SpaceX's Crew Dragon** to prepare to abandon ship. The plans were dropped, and Roscosmos has agreed to permanently close off the leaking PrK transfer tunnel from the rest of the station. * **Policy Impact:** Due to these technical failures and commercial replacement delays, the U.S. Senate Commerce Committee advanced legislation to **extend the life of the ISS from 2030 to 2032** to avoid a low-Earth orbit gap where China's Tiangong would be the sole inhabited station. * **Durable Slug:** `iss-zvezda-leak-standoff-decommissioning-extension` *(New Finding)* * **Watch Event:** Recorded progress on the ongoing watch `ISS Russian Zvezda module air leaks and repairs`. ### 5. **Pfizer’s Seagen-Acquired ADC Fails Phase 3 Trial** * **What Happened:** On June 22, 2026, Pfizer announced that its investigational antibody-drug conjugate (ADC) **sigvotatug vedotin** (acquired in the $43 billion Seagen deal) failed to meet its primary overall survival (OS) endpoint vs. docetaxel in the Phase 3 SigVie-002 study for second-line metastatic non-squamous NSCLC. * **Strategic Implications:** This is the third Seagen-acquired ADC setback in a year, challenging Pfizer's high-stakes oncology strategy. Pfizer is pinning its hopes on an ongoing first-line NSCLC combination trial with Keytruda, with data expected in 2027. * **Durable Slug:** `pfizer-sigvotatug-vedotin-phase-3-lung-cancer-fail` *(New Finding)* ### 6. **BridgeBio’s Oral Achondroplasia Drug Achieves Breakthrough in NEJM** * **What Happened:** On June 29, 2026, BridgeBio published Phase 3 PROPEL 3 results for once-daily **oral infigratinib** in children with achondroplasia in the *New England Journal of Medicine* (NEJM). The drug met its primary endpoint, showing a highly significant annualized height velocity (AHV) difference of **+1.74 cm/year** vs. placebo ($p < 0.0001$), with a clean safety profile. * **Competitive Threat:** Oral infigratinib represents a major competitive threat to BioMarin's daily-injection Voxzogo. BridgeBio plans to submit an NDA to the FDA in **Q3 2026** for a potential U.S. launch in early-to-mid 2027. * **Durable Slug:** `bridgebio-infigratinib-achondroplasia-nejm-phase-3` *(New Finding)* ### 7. **AI-Designed Universal Coronavirus Vaccine Clears Phase 1** * **What Happened:** Research from the University of Cambridge and DIOSynVax published in the *Journal of Infection* showed that their AI-designed pan-sarbecovirus vaccine candidate **pEVAC-PS** cleared Phase I safety testing in 39 healthy adults. The DNA plasmid vaccine, delivered needle-free via the PharmaJet Tropis device, successfully directed immune responses toward conserved regions shared by SARS-CoV-1, SARS-CoV-2, and bat coronaviruses. * **Limitations:** The immune response was characterized as "modest and variable," heavily confounded by participants' high pre-existing background immunity. A Phase II trial with 200 participants is currently underway to further assess efficacy. * **Durable Slug:** `diosynvax-ai-universal-coronavirus-vaccine-phase-1` *(New Finding)* * **Watch Event:** Recorded progress on the active watch `DIOSynVax AI-designed universal Sarbeco vaccine Phase II trial readout`.